COMPANY INFO
Gallant is a private biotechnology company founded in 2018 by Aaron Hirschhorn. It specializes in developing a pet health technology platform that provides stem cell therapy and regenerative medicine to treat pets by leveraging their natural biology to avoid traditional medications and surgeries. The company is headquartered in San Diego, California, and has approximately 50 employees. Gallant's mission is to make regenerative care more accessible and effective for pets, helping to extend their healthy years. Their website is https://www.gallant.com. The industry focus is Biotechnology, specifically veterinary regenerative medicine. Aaron Hirschhorn was the founder and CEO until his passing in 2021, and the current CEO is Dr. Linda Black, DVM, PhD.
Gallant Pet, Inc. is an innovative biotechnology company founded in 2018 with headquarters in San Diego, California. Operating in the veterinary regenerative medicine sector, Gallant develops cutting-edge pet health technology, focusing on stem cell therapy and regenerative solutions to improve quality of life for pets. With around 53 employees, Gallant is led by CEO Dr. Linda Black, DVM, PhD, and aims to make advanced regenerative care accessible, effective, and widely available for companion animals.
Gallant Pet, Inc. funding has been significant, with approximately $93.4 million raised over numerous rounds. Since its inception, the company has completed at least nine funding rounds, beginning with seed capital in 2018 and advancing to later-stage venture capital as recently as September 2024. The company’s funding strategy has focused on securing capital to fuel product development, expand into new markets, support clinical trials, and accelerate the adoption of FDA-approved stem cell therapies for pets. Notable Gallant Pet, Inc. investors include Digitalis Ventures, BOLD Capital Partners, Maveron, The Finger Group, and Slow Ventures, among others.
Gallant’s latest Later Stage VC round raised $27.1 million, aimed at driving revenue growth, scaling operations, and supporting further clinical trial and product commercialization efforts in the veterinary regenerative medicine space.
This Series A round of $25.5 million was earmarked for advancing product development, expanding Gallant’s national reach, and entering new veterinary markets.
Gallant’s $2 million seed round provided initial funding for company launch activities, early research, and development of their proprietary stem cell therapy platform for pets.
The earliest seed funding of $46,000 supported proof of concept, foundational research, and organizational establishment efforts.
Digitalis Ventures is a life sciences investment firm that has backed Gallant Pet, Inc. across multiple funding rounds, providing critical resources and strategic guidance to help drive the company's growth in animal health innovations.
BOLD Capital Partners has contributed to Gallant Pet, Inc. funding rounds, providing both capital and expertise to support expansion in biotechnology and regenerative medicine.
Hill Creek Partners, an early-stage and growth equity investor, was instrumental in supporting Gallant’s growth through its involvement in key funding rounds, particularly for scaling operations.
NovaQuest Capital Management, with deep expertise in healthcare and life sciences investments, helped bolster Gallant’s Series A and later stage rounds, strengthening its financial and strategic foundation.
The Finger Group played a significant role in the most recent funding round, contributing as a lead investor to support Gallant’s product commercialization and market expansion initiatives.
Maveron participated in Gallant Pet, Inc. investors syndicates, enabling key advancements in research and market entry for new regenerative therapies.
Slow Ventures’ involvement brought early-stage support and innovation capital, helping Gallant build out its core technology and establish a foothold in the pet biotech industry.
Websets is a powerful natural language search and data enrichment tool that helps you discover comprehensive funding information for any company. Whether you're researching Gallant Pet, Inc. funding rounds or exploring investment data for other companies, Websets provides detailed insights into funding history, investors, and financial milestones.
With Websets, you can access detailed funding profiles, investor information, and financial data through intuitive natural language queries. Sign up now to enhance your funding research capabilities.